Skip to main content
See every side of every news story
Published loading...Updated

Lilly Commits Additional $4.5 Billion in Indiana Manufacturing Sites

The company said the expansion will support genetic medicines and weight-loss drugs, and bring total Indiana capital commitments since 2020 above $21 billion.

  • On Wednesday, Eli Lilly and Company announced a $4.5 billion investment across two Lebanon, Indiana sites, pushing total state capital expansion commitments since 2020 to more than $21 billion.
  • Lilly described the Lebanon campus as the "cornerstone of Lilly's domestic manufacturing buildout," strengthening U.S. production amid global pressure to manufacture medicines domestically rather than import them.
  • The investment expands production capacity for Zepbound and Mounjaro at the Lebanon API site, while supporting future manufacturing of Foundayo and retatrutide, an investigational obesity treatment.
  • Indiana Gov. Mike Braun and Mayor Matt Gentry praised the expansion, with Gentry stating, "The promise we made to strengthen our economy and provide new opportunities for our citizens is being fulfilled."
  • The company is selling about $8 billion in bonds to fund this buildout, part of a broader strategy involving more than $30 billion in deals this year to diversify pipelines ahead of upcoming patent losses.
Insights by Ground AI

21 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 43% of the sources are Center
43% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

WRTV broke the news on Wednesday, May 6, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal